Israel has partnered with NRx Pharmaceuticals to complete trials and commercialize the Israeli-developed COVID-19 vaccine, BriLife. NRx and the Israel Institute for Biological Research  and Defense Ministry announced this week a memorandum of understanding that includes the worldwide development, manufacturing and marketing rights of the vaccine, which in recent months has been undergoing early clinical trials in Israel. NRx is to undertake phase three trials of the vaccine in Israel and abroad. BriLife is a self-propagating live virus vaccine based on a previous FDA-approved vaccine platform. Dr. Jonathan Javitt, founder and CEO of NRx Pharmaceuticals, told KAN reporter Naomi Segal that the Israeli-developed vaccine has potential to rapidly adapt to the variants of the virus.